No Patent Rights. or other intellectual property rights licensed to Acceleron under either (a) that certain Exclusive License Agreement dated August 10, 2010 between Acceleron and the Salk Institute for Biological Studies or (b) that certain Exclusive License Agreement dated August 11, 2010 between Acceleron and the Salk Institute for Biological Studies relate to or are necessary or useful to Develop, Manufacture or Commercialize a Licensed Compound or a Licensed Product in the Field. Celgene shall not have any obligations under (including any financial obligations), or be subject to any restrictions set forth in, either such agreement with Salk Institute for Biological Studies.
Appears in 5 contracts
Samples: License and Option Agreement (Acceleron Pharma Inc), License and Option Agreement (Acceleron Pharma Inc), License and Option Agreement (Acceleron Pharma Inc)
